Printed from Voxsanity (voxsanity.com.au) — NCT04919629 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Recruiting
NCT04919629
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older at the time of signing the consent form
- People with recurrent (returned) epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer of certain types, or people with cancer affecting both the ovary and uterus at the same time — regardless of how the cancer responded to platinum-based chemotherapy, what stage it was, or how many previous treatments were received
- People whose cancer is causing a build-up of fluid in the abdomen or chest (or both) that has needed to be drained at least once in the 4 weeks before joining the study, or who already have a drainage tube in place to manage symptoms
- People with a general health/activity level rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
- People who have not received pembrolizumab or a similar immune checkpoint inhibitor drug in the 9 weeks before enrolling
- People with a life expectancy of at least 3 months
- People whose recent blood test results meet certain minimum standards for white blood cells, platelets, haemoglobin, kidney function, liver function, protein levels, and blood clotting (confirm specific values with the trial site)
- Women who could potentially become pregnant must have a negative pregnancy test within 72 hours before the first dose of study treatment
- People who are willing and able to self-administer one of the study drugs (APL-2) by injection, or have a carer who can do this
- People who have no known medical reason preventing them from receiving bevacizumab or pembrolizumab, as assessed by the enrolling doctor
- People who are willing to receive certain vaccinations (against meningitis, pneumococcal disease, and Haemophilus influenzae) if assigned to receive APL-2 and not already vaccinated
- People who understand the study's investigational nature and are willing to sign a written consent form before any study procedures begin
- People of childbearing potential who are willing to use two methods of contraception, or are surgically sterile, or abstain from heterosexual activity throughout the study and for 120 days after the last dose
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People currently receiving other cancer treatments, or who have taken part in another clinical trial or used an investigational drug or device within 3 weeks of the first planned study dose
- People with an immune deficiency diagnosis, or who are currently taking steroid or immunosuppressive medications (within 7 days before the first dose), or any medication that may affect immune function
- People with an active autoimmune disease that has required systemic treatment (such as immune-modifying drugs or steroids) in the past 3 months — note that standard hormone or gland replacement therapies are not considered a reason for exclusion
- People with an active infection currently requiring treatment with systemic medication (such as intravenous antibiotics)
- People with a significant heart or blood vessel condition, including: uncontrolled high blood pressure; a heart attack or unstable chest pain within the past 6 months; moderate-to-severe heart failure; moderate-to-severe peripheral vascular disease; or clinically significant peripheral artery disease within the past 6 months
- People who are pregnant or currently breastfeeding
- People who are unwilling or unable to follow the requirements of the study protocol
- People for whom the treating doctor considers participation in the study to be unsuitable for any reason
- People with a history of non-infectious lung inflammation (pneumonitis or interstitial lung disease) that required steroid treatment, or who currently have this condition
- People with a known history of HIV infection
- People with both active hepatitis B and active hepatitis C infections at the same time
- People who have received an investigational (unlicensed and not emergency-approved) vaccine — note that approved COVID-19 vaccines of certain types are permitted
- People with another cancer that is currently progressing or has required active treatment within the past 2 years — note that certain treated skin cancers or carcinoma in situ (excluding bladder) may not be a reason for exclusion (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
27 April 2023
Est. completion
30 April 2028
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Incidence of adverse events (Phase 2a); Accumulation of effusion (Phase 2b)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.